Stock AnalizRoyalty Pharma (RPRX) earnings for the quarter ended September 2026: EPS beats estimates
Royalty Pharma reported results for the quarter ended September 2026 on November 4, 2026. Adjusted earnings per share came in at $1.21 against the analysts’ average forecast of $1.18, a beat of 2.4%.
Revenue for the quarter was $690 million, up 13.3% from $609 million in the same quarter a year earlier.
The market’s verdict: the stock rose 1.8% on the first trading day after the report.
The last four quarters
Royalty Pharma has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $1.21 | $1.18 | +2.4% | +13% | +1.8% |
| Jun 2026 | $1.32 | $1.27 | +3.9% | +16% | −0.4% |
| Mar 2026 | $1.30 | $1.18 | +9.4% | +11% | −0.5% |
| Dec 2025 | $1.47 | $1.33 | +9.9% | +5% | +1.3% |
What comes next
Analysts expect EPS of $1.57 for the next quarter on average and $5.39 for the fiscal year ending December 31, 2026.
The average analyst price target is $72.00, 4% above the current price of $69.31.
Valuation and score
Royalty Pharma scores 2.2 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 45.9, and its intrinsic value under moderate assumptions is about 20% above the current market value. Full Royalty Pharma analysis with 10 years of financials
Frequently asked questions
What was Royalty Pharma’s EPS for the quarter ended September 2026?
$1.21 adjusted per share, against an analyst consensus of $1.18.
How much revenue did Royalty Pharma report?
$690 million, up 13.3% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.